var title_f6_6_6240="Large pericardial effusion";
var content_f6_6_6240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis precordial view shows a large anterior (APE) and posterior pericardial effusion (PPE). This distinction between this large effusion and a moderate sized one is the easily seen anterior accumulation. Since the volume of the effusion is a cube function of its dimensions, its presence circumferentially makes a large difference in it volume without a major qualitative change in appearance.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; LA: left atrium; dAo: descending aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6240=[""].join("\n");
var outline_f6_6_6240=null;
var title_f6_6_6241="MRI Schwannoma";
var content_f6_6_6241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A schwannoma of the brachial plexus by MRI imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 240px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) T1 showing a rounded mass with homogeneous signal intensity similar to muscle. B) T2 showing the same mass with high signal intensity, especially on the periphery. C) T1 with gadolinium showing homogeneous enhancement except for a small rim, suggesting encapsulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James M Gilchrist, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6241=[""].join("\n");
var outline_f6_6_6241=null;
var title_f6_6_6242="Palmar rash secondary syphilis";
var content_f6_6_6242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maculopapular rash on the palms, which rarely can be pustular, in a patient with secondary syphilis. Patients can be quite contagious at this stage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David H Martin and Tomasz F Mroczkowski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6242=[""].join("\n");
var outline_f6_6_6242=null;
var title_f6_6_6243="Parenchymal brain lesions";
var content_f6_6_6243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Parenchymal brain lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Bilateral thalamic edema in a case of deep cerebral venous system thrombosis, identified in a T2-weighted FLAIR MRI. B) T2-weighted FLAIR MRI (coronal view) showing left temporal hemorrhagic infarct due to a thrombosis of left lateral sinus (arrow).",
"    <div class=\"footnotes\">",
"     Flair: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6243=[""].join("\n");
var outline_f6_6_6243=null;
var title_f6_6_6244="Peritonsillar space";
var content_f6_6_6244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Peritonsillar space anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6244=[""].join("\n");
var outline_f6_6_6244=null;
var title_f6_6_6245="Hypokalemia-induced renal dysfunction";
var content_f6_6_6245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypokalemia-induced renal dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6245/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6245/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6245/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6245/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6245/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6245/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/6/6245/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia, especially if persistent, can induce a variety of changes in renal function, impairing tubular transport and possibly inducing chronic tubulointerstitial disease and cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. One function that is not impaired is the ability to appropriately conserve potassium, which can be important in distinguishing between extrarenal and renal sources of potassium loss when the cause of hypokalemia is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H139467157\">",
"     'Renal potassium conservation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link&amp;anchor=H60964991#H60964991\">",
"     \"Evaluation of the patient with hypokalemia\", section on 'Assessment of urinary potassium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following renal abnormalities, most of which are reversible with potassium repletion, can be induced by hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired urinary concentrating ability",
"     </li>",
"     <li>",
"      Intracellular acidosis",
"     </li>",
"     <li>",
"      Increased ammonia production",
"     </li>",
"     <li>",
"      Increased bicarbonate reabsorption",
"     </li>",
"     <li>",
"      Altered sodium reabsorption",
"     </li>",
"     <li>",
"      Hypokalemic nephropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impaired urinary concentrating ability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypokalemia (plasma potassium concentration usually &le;3.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can lead to a modest reduction in urinary concentrating ability. The magnitude of the concentrating defect was evaluated in a study in which hypokalemia was induced by a low potassium diet (0.1",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    per day) in nine men [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/7\">",
"     7",
"    </a>",
"    ]. The maximum urine osmolality fell from a mean of 1140",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    at baseline to 328",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    at four weeks despite the administration of exogenous vasopressin. Most of the reduction in concentrating ability occurred in the first two weeks. The ability to excrete a dilute urine was not impaired.",
"   </p>",
"   <p>",
"    The concentrating defect induced by hypokalemia is associated with decreased collecting tubule responsiveness to antidiuretic hormone (ie, nephrogenic diabetes insipidus). How this occurs is incompletely understood. Two factors that play at least a contributory role are decreased expression of aquaporin-2, the water channel that fuses with the luminal membrane under the influence of antidiuretic hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/8\">",
"     8",
"    </a>",
"    ], and decreased activity of Na-K-2Cl cotransporter in the thick ascending limb, which plays a central role in generating the countercurrent gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hypokalemia may complain of polyuria and polydipsia. However, as illustrated by the above observations, the concentrating defect is not usually severe enough to account for these symptoms. Studies in animals suggest that potassium depletion may be a primary stimulus to thirst [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7551452\">",
"    <span class=\"h2\">",
"     Intracellular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of hypokalemia and potassium depletion causes potassium to exit from cells and this net outward movement of cations is generally counterbalanced by a movement of protons into cells. The net effect is intracellular acidosis and some degree of extracellular alkalosis. The development of intracellular acidosis within renal tubular cells has several effects described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Increased ammonia production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia increases renal tubular production of ammonia, which then enters both the tubular lumen and the peritubular capillary [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/12\">",
"     12",
"    </a>",
"    ]. This effect is partially related to intracellular acidosis within renal tubular cells (described above), which increases the production of ammonia from glutamine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/13\">",
"     13",
"    </a>",
"    ], a process that is appropriate when the intracellular acidosis occurs in the setting of metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. The hypokalemia-induced increase in ammonia entry into the renal vein may be clinically important in patients with advanced cirrhosis, possibly precipitating hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link&amp;anchor=H3#H3\">",
"     \"Hepatic encephalopathy in adults: Treatment\", section on 'Treatments based upon the ammonia hypothesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Increased bicarbonate reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intracellular acidosis induced by hypokalemia promotes increased secretion of hydrogen ions, which can react with luminal bicarbonate, leading to bicarbonate reclamation or to urinary buffers such as ammonia to produce ammonium. This increase in hydrogen ion secretion increases net bicarbonate reabsorption and can contribute to the maintenance of a metabolic alkalosis, since it prevents the excretion of the excess bicarbonate in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of metabolic alkalosis\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Increased sodium reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate hypokalemia can impair the ability to excrete a sodium load by increasing sodium reabsorption in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Although the mechanisms are incompletely understood, hypokalemia-induced intracellular acidosis in proximal tubular cells (described above) may stimulate the Na-H exchanger in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. This will act to restore a normal intracellular pH and simultaneously enhance sodium reabsorption. The resulting sodium retention produces volume expansion and can modestly elevate the blood pressure (up to 5 mmHg), an effect that may be important in patients with hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=see_link\">",
"     \"Potassium and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an opposite effect may occur with severe hypokalemia (plasma potassium concentration usually below 2",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    In this setting, maximum sodium chloride reabsorption is impaired, resulting in an inability to lower the urine chloride concentration below 15",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the presence of volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/18\">",
"     18",
"    </a>",
"    ]. The mechanism by which this occurs is unclear, but diminished reabsorption in the loop of Henle and collecting tubules appear to play at least a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/10\">",
"     10",
"    </a>",
"    ]. As noted above, reduced loop of Henle reabsorption also contributes to the concentrating defect induced by hypokalemia. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Impaired urinary concentrating ability'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypokalemic nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic potassium depletion in humans produces characteristic, although non-specific vacuolar lesions in the epithelial cells in the proximal tubule and occasionally the distal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. This abnormality generally requires at least one month to develop and is readily reversible with potassium repletion. However, prolonged hypokalemia (as with surreptitious diuretic use, eating disorders, laxative abuse, or primary aldosteronism) can lead to more severe changes, including interstitial nephritis and fibrosis, tubular atrophy, and cyst formation that is most prominent in the renal medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/5,6,19\">",
"     5,6,19",
"    </a>",
"    ]. Correction of the hypokalemia can lead to a decrease in the number and size of cysts, although the tubulointerstitial lesions and associated renal insufficiency may be irreversible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Acute renal failure at least in part induced by hypokalemia has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of these changes is not well understood. One hypothesis that has been documented in experimental animals is that the hypokalemia-induced increase in renal ammonium production described above results in ammonia accumulation in the interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/21\">",
"     21",
"    </a>",
"    ]. This ammonia can activate complement, which may then damage the tubular cells. The associated intracellular acidosis is a stimulus for cell growth that could account for the cellular proliferation required for cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible explanation for renal injury is alterations in growth factors and cytokines in response to hypokalemia. These include vascular endothelial growth factor, insulin growth factor-I, insulin growth factor binding protein-1, angiotensin II, monocyte chemoattractant protein-1,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transforming growth factor-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139467157\">",
"    <span class=\"h1\">",
"     RENAL POTASSIUM CONSERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One renal function that is not impaired in hypokalemia is the ability to appropriately conserve potassium by both decreasing distal potassium secretion and increasing active distal potassium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with hypokalemia\", section on 'Regulation of potassium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This response is important clinically, since it allows measurement of urinary potassium excretion to distinguish between extrarenal and renal losses as the cause of otherwise unexplained hypokalemia. Potassium excretion should be less than 25",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    with extrarenal losses (or with diuretic therapy after the effect of the drug has worn off) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6245/abstract/26\">",
"     26",
"    </a>",
"    ]. In comparison, a higher value usually indicates at least some component of renal potassium wasting as might be seen with diuretic therapy, one of the forms of primary aldosteronism, or during the bicarbonaturic phase in a patient with vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link&amp;anchor=H60964991#H60964991\">",
"     \"Evaluation of the patient with hypokalemia\", section on 'Assessment of urinary potassium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695307564\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic hypokalemia (plasma potassium concentration usually &le;3.0",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      can lead to a modest reduction in urinary concentrating ability. The associated polyuria and polydipsia that may be present cannot be explained by the concentrating defect and may reflect hypokalemia-induced stimulation of thirst. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Impaired urinary concentrating ability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypokalemia increases the tubular production of ammonia, which then enters both the tubular lumen and the peritubular capillary.",
"     </li>",
"     <li>",
"      The associated increase in ammonia entry into the renal vein may be clinically important in patients with advanced cirrhosis, possibly precipitating hepatic encephalopathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Increased ammonia production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increase in acid secretion, both as free hydrogen ions and as ammonium, in response to the intracellular acidosis induced by hypokalemia promotes net bicarbonate reabsorption. This effect can contribute to the maintenance of a concurrent metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Increased bicarbonate reabsorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild to moderate hypokalemia can impair the ability to excrete a sodium load, at least in part by increasing proximal sodium reabsorption. This sodium retention and subsequent volume expansion can produce a modest elevation in blood pressure (up to 5 mmHg), an effect that may be important in patients with hypertension. However, severe hypokalemia may have the opposite effect and increase NaCl excretion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased sodium reabsorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic potassium depletion produces characteristic, although non-specific vacuolar lesions in the epithelial cells in the proximal tubule and occasionally the distal tubule. This abnormality generally requires at least one month to develop and is readily reversible with potassium repletion. However, prolonged hypokalemia can lead to more severe changes, including interstitial nephritis and fibrosis, tubular atrophy, and cyst formation that is most prominent in the renal medulla. Correction of the hypokalemia can lead to a decrease in the number and size of cysts, although the tubulointerstitial lesions and associated renal insufficiency may be irreversible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypokalemic nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mount DB, Zandi-Nejad K. Disorders of potassium balance. In: Brenner and Rector's The Kidney, Brenner BM (Ed), W.B Saunders, Philadelphia 2008. p.547.",
"    </li>",
"    <li>",
"     Mujais SK, Katz AL. Potassium deficiency. In: The Kidney: Physiology and Pathophysiology, Seldin DW, Giebisch G (Eds), Lippincott Williams &amp; Wilkins, 2000. p.1615.",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.860.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/4\">",
"      Schwartz WB, Relman AS. Effects of electrolyte disorders on renal structure and function. N Engl J Med 1967; 276:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/5\">",
"      Riemenschneider T, Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. Clin Nephrol 1983; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/6\">",
"      Torres VE, Young WF Jr, Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med 1990; 322:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/7\">",
"      RUBINI ME. Water excrtion in potassium-deficient man. J Clin Invest 1961; 40:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/8\">",
"      Marples D, Fr&oslash;kiaer J, D&oslash;rup J, et al. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 1996; 97:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/9\">",
"      Elkjaer ML, Kwon TH, Wang W, et al. Altered expression of renal NHE3, TSC, BSC-1, and ENaC subunits in potassium-depleted rats. Am J Physiol Renal Physiol 2002; 283:F1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/10\">",
"      Luke RG, Booker BB, Galla JH. Effect of potassium depletion on chloride transport in the loop of Henle in the rat. Am J Physiol 1985; 248:F682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/11\">",
"      Berl T, Linas SL, Aisenbrey GA, Anderson RJ. On the mechanism of polyuria in potassium depletion. The role of polydipsia. J Clin Invest 1977; 60:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/12\">",
"      Tizianello A, Garibotto G, Robaudo C, et al. Renal ammoniagenesis in humans with chronic potassium depletion. Kidney Int 1991; 40:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/13\">",
"      COOKE RE, SEGAR WE, CHEEK DB, et al. The extrarenal correction of alkalosis associated with potassium deficiency. J Clin Invest 1952; 31:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/14\">",
"      Jaeger P, Karlmark B, Giebisch G. Ammonium transport in rat cortical tubule: relationship to potassium metabolism. Am J Physiol 1983; 245:F593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/15\">",
"      Gabduzda GJ, Hall PW 3rd. Relation of potassium depletion to renal ammonium metabolism and hepatic coma. Medicine (Baltimore) 1966; 45:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/16\">",
"      Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966; 51:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/17\">",
"      Sabatini S, Kurtzman NA. The maintenance of metabolic alkalosis: factors which decrease bicarbonate excretion. Kidney Int 1984; 25:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/18\">",
"      Garella S, Chazan JA, Cohen JJ. Saline-resistant metabolic alkalosis or \"chloride-wasting nephropathy\". Report of four patients with severe potassium depletion. Ann Intern Med 1970; 73:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/19\">",
"      Cremer W, Bock KD. Symptoms and course of chronic hypokalemic nephropathy in man. Clin Nephrol 1977; 7:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/20\">",
"      Menahem SA, Perry GJ, Dowling J, Thomson NM. Hypokalaemia-induced acute renal failure. Nephrol Dial Transplant 1999; 14:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/21\">",
"      Tolins JP, Hostetter MK, Hostetter TH. Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest 1987; 79:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/22\">",
"      Alpern RJ, Toto RD. Hypokalemic nephropathy--a clue to cystogenesis? N Engl J Med 1990; 322:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/23\">",
"      Tsao T, Fawcett J, Fervenza FC, et al. Expression of insulin-like growth factor-I and transforming growth factor-beta in hypokalemic nephropathy in the rat. Kidney Int 2001; 59:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/24\">",
"      Suga S, Mazzali M, Ray PE, et al. Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency. Kidney Int 2002; 61:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/25\">",
"      Reungjui S, Roncal CA, Sato W, et al. Hypokalemic nephropathy is associated with impaired angiogenesis. J Am Soc Nephrol 2008; 19:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6245/abstract/26\">",
"      SQUIRES RD, HUTH EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest 1959; 38:1134.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2295 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6245=[""].join("\n");
var outline_f6_6_6245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H695307564\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impaired urinary concentrating ability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7551452\">",
"      Intracellular acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Increased ammonia production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Increased bicarbonate reabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Increased sodium reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypokalemic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H139467157\">",
"      RENAL POTASSIUM CONSERVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H695307564\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=related_link\">",
"      Evaluation of the patient with hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=related_link\">",
"      Potassium and hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_6_6246="Factitious diarrhea";
var content_f6_6_6246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Factitious diarrhea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6246/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6246/contributors\">",
"     Arnold Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6246/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6246/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6246/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/6/6246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term factitious (or factitial) has been used in medical parlance to imply covert human activity. The consideration of such a possibility often changes the patient-physician relationship, leading the physician to feel deceived and the patient to feel mistrusted. However, the pejorative connotation with which factitious illness has been encumbered requires softening because some patients with factitious disease suffer through no fault of their own. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a thorough search for the etiology of an illness is unrevealing, the possibility of a self-induced illness must be considered. Factitious illness occurs more frequently than is probably recognized, since it falls outside the usual expectations concerning causation of disease. Nonetheless, such a condition is a true illness, although the pathogenesis must be redefined as emotional rather than physical. Factitious diarrhea is a characteristic example of such an illness.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of factitious diarrhea will be reviewed here. This topic review will also consider factitious illnesses in general, with emphasis on the most severe form of this disorder, Munchausen syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS OF FACTITIOUS DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious diarrhea may be characterized by a true increase in stool volume, which is self-induced, or the creation of an apparent increase in stool volume by the addition of various substances to the stool. Surreptitious laxative abuse is the most frequent cause of factitious diarrhea, and often presents as chronic watery diarrhea of unknown etiology. As many as 15 percent of patients referred to tertiary care centers for evaluation of chronic diarrhea were found to have laxative abuse as the cause of their diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/1\">",
"     1",
"    </a>",
"    ]. Prior to making this diagnosis, an evaluation to rule out common organic causes of diarrhea should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    .) It is important to emphasize that not all patients with factitious diarrhea abuse laxatives since some individuals may be unaware of the relationship between laxatives and diarrhea or that medications used for other conditions contain substances that can cause diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of patients with factitious diarrhea are women, many of whom are from higher socioeconomic classes, are often intelligent and educated, and may be employed in a medical field. These patients often seek care from many physicians, and have multiple hospital admissions in an effort to establish the cause of the diarrhea. They also have a higher incidence of anorexia nervosa, suggesting a common underlying psychiatric abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laxative abuse often presents as watery diarrhea that is high in frequency and volume [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Patients report between 10 and 20 bowel movements a day, with 24-hour stool volumes ranging from 300 to 3000 mL. More than 50 percent of patients complain of nocturnal bowel movements, which are not characteristic of functional diarrhea, such as irritable bowel syndrome. Some patients also have blood in the stool, making the true diagnosis even more difficult to determine.",
"      <br/>",
"      <br/>",
"      The diarrhea is often associated with crampy abdominal pain. This is a direct effect of many laxatives, which increase the fluid content of the stool and enhance gastrointestinal motility.",
"     </li>",
"     <li>",
"      Weight loss is common, and can be severe enough to result in cachexia. Multiple factors may contribute to weight loss other than the diarrhea. These include concurrent nausea or vomiting (which may be seen with laxative abuse alone or in patients with anorexia and bulimia who use laxatives in an effort to lose weight) and diminished nutrient absorption. Some laxatives have a direct inhibitory effect on nutrient absorption. As an example, rhein (an anthraquinone) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"       bisacodyl",
"      </a>",
"      (a diphenolic laxative) impair glucose absorption. These compounds may also cause mild steatorrhea and gastrointestinal protein loss.",
"     </li>",
"     <li>",
"      Lethargy and generalized weakness, in addition to muscle weakness, are prominent symptoms of laxative abuse. Malnutrition, dehydration, and hypokalemia may result.",
"     </li>",
"     <li>",
"      Laxative abuse may also be associated with a number of fluid and electrolyte disorders:",
"      <br/>",
"      <br/>",
"      Volume depletion, which can lead to orthostatic hypotension due to sodium and water loss in the stool.",
"      <br/>",
"      <br/>",
"      Hypokalemia is frequently present due primarily to losses in the diarrheal fluid. Hypovolemia-induced secondary hyperaldosteronism may also contribute by increasing colonic potassium secretion. Interestingly, urinary potassium excretion is not increased by secondary hyperaldosteronism since the stimulatory effect of aldosterone is offset by the decrease in sodium delivery to the potassium secretory site in the collecting tubule.",
"      <br/>",
"      <br/>",
"      Diarrhea, particularly severe acute diarrhea, is classically associated with metabolic acidosis due to the rapid loss of large amounts of bicarbonate [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. However, the chronic diarrhea caused by laxative abuse often results in metabolic alkalosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. The alkalosis may be due in part to hypokalemia impairing the intestinal reabsorption of chloride, thereby diminishing bicarbonate secretion into the intestinal lumen via chloride-bicarbonate exchange. Loss of a high-chloride, low-bicarbonate solution can raise the plasma bicarbonate concentration, and both volume depletion and hypokalemia prevent excretion of the excess bicarbonate in the urine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link\">",
"       \"Pathogenesis of metabolic alkalosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Moderate to severe hypermagnesemia can occur if a magnesium-containing cathartic is used, particularly in those patients where urinary magnesium excretion is impaired because of volume depletion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION FOR FACTITIOUS DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the history, evaluation of the patient with suspected factitious diarrhea consists of stool analysis, attempted detection of chemical laxatives, and endoscopic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/9\">",
"     9",
"    </a>",
"    ]. An adequate evaluation for suspected laxative abuse can usually be performed on an outpatient basis. After organic causes of chronic diarrhea are ruled out, the following flow chart may be used to evaluate the cause of factitious diarrhea (",
"    <a class=\"graphic graphic_algorithm graphicRef58754 \" href=\"UTD.htm?31/20/32078\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stool analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool analysis consists of measurement of stool osmolality, and sodium, potassium, and magnesium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/9\">",
"     9",
"    </a>",
"    ]. An osmolal gap (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/42/9890?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) indicates the presence of an unmeasured solute which can be due to laxatives containing magnesium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , lactose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    , or polyethylene glycol as the active ingredients. The osmotic gap in these settings usually exceeds 50",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    compared to a gap that is generally less than 50",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in secretory diarrheas. The other disorders that can cause a secretory diarrhea are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef65916 \" href=\"UTD.htm?8/6/8299\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The osmolar gap is calculated by subtracting twice the measured concentrations of sodium and potassium from 290-300",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    which is the expected osmolality of freshly passed diarrheal stool.",
"   </p>",
"   <p>",
"    Measurement of stool magnesium may be helpful if there is a substantial osmotic gap [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/7\">",
"     7",
"    </a>",
"    ]. A value above 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (45",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or 90",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    suggests magnesium-induced diarrhea. Screening of stool water or urine by thin layer chromatography (see below) will not detect magnesium-containing cathartics.",
"   </p>",
"   <p>",
"    Measurement of stool osmolality can also detect factitious diarrhea resulting from the addition of water to the stool [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This diagnosis should be suspected if the measured stool osmolality is lower than that of plasma since the colon cannot dilute stool to an osmolality which is less than that of plasma.",
"   </p>",
"   <p>",
"    Stool osmolality significantly higher than plasma (particularly with a high sodium concentration) raises the possibility that urine has contaminated the stool. This can be confirmed by demonstrating high concentrations of urea and creatinine in the stool water. The stool osmolality may also increase if the stool is not examined quickly due to breakdown by bacteria of carbohydrates into smaller, osmotically active molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Detection of chemical laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laxatives can be detected in the serum, stool, and urine. Serum concentrations are generally low, and reach maximal levels one to two hours after ingestion. Urine concentrations may be up to 10 times higher than plasma concentrations; thus, testing the urine provides the best yield for laxative detection (",
"    <a class=\"graphic graphic_table graphicRef52611 \" href=\"UTD.htm?2/2/2091\">",
"     table 2",
"    </a>",
"    ). Many over-the-counter laxatives used to contain phenolphthalein, which was reclassified because of carcinogenic effects in animals, and is no longer available over-the-counter in the United States. Phenolphthalein could be identified using a test that can be performed at the bedside. Stool samples turn pink-red when alkalinized with NaOH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/3\">",
"     3",
"    </a>",
"    ]; another laxative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    , turns purple-blue in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/9\">",
"     9",
"    </a>",
"    ]. Such assays should be abandoned because they are not sufficiently sensitive; they should be replaced by spectrophotometric or chromatographic assays [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Broad screening methods for both diphenolic laxatives and anthraquinones can be done in most hospital laboratories with mass spectrometry or gas chromatography, although the accuracy of these methods is incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/12\">",
"     12",
"    </a>",
"    ]. Polyethylene glycol containing laxatives should specifically be measured in the stool or urine because of the widespread use of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/13\">",
"     13",
"    </a>",
"    ]. The sample may be sent in a small plastic container, and the use of serum separator tubes is not recommended. To date, there have been no reported cases of factitious diarrhea associated with polyethylene glycol use. Many patients consume one or more of these agents at a time, or may rotate agents, necessitating screening for all types of laxatives. As noted above, these methods will not detect magnesium. Repeated analyses of stool and urine is wise, since patients may ingest laxatives intermittently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endoscopic or radiologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic or radiologic examination of the colon may be helpful in some patients. Melanosis coli is a lesion that occurs only with the use of anthraquinone-containing laxatives; it is not seen with osmotic or diphenolic agents. Melanosis coli can develop within four months of the onset of laxative ingestion and can disappear in the same amount of time if laxative use in discontinued. It appears as a dark brown discoloration of the colon with lymph follicles shining through as pale patches (",
"    <a class=\"graphic graphic_picture graphicRef50472 \" href=\"UTD.htm?42/29/43474\">",
"     picture 1",
"    </a>",
"    ). These findings may be evident in the rectum and sigmoid colon, although the entire colon may be involved. If not evident on endoscopy, melanosis coli may be demonstrated histologically by finding pigment in the macrophages of the lamina propria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/14\">",
"     14",
"    </a>",
"    ]. It must be emphasized that melanosis coli is not specific to exposure to anthraquinone laxatives.",
"   </p>",
"   <p>",
"    Cathartic colon is a rarely seen but severe manifestation of prolonged laxative use. It is characterized by dilation of the large bowel, with decreased or absent haustrations noted on plain abdominal films or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema. The changes are usually most marked in the right colon, but can affect the entire colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Room search",
"    </span>",
"    &nbsp;&mdash;&nbsp;Searching the patient's room and possessions for laxatives or paraphernalia used for deception is often a successful method used to support a diagnosis of factitious diarrhea. Although it raises an ethical dilemma concerning invasion of the patient's privacy, it may be justified on grounds that a correct diagnosis will eliminate further diagnostic testing, and accelerate the initiation of appropriate therapy.",
"   </p>",
"   <p>",
"    Although often highly successful in confirming a suspected diagnosis of laxative abuse, a room search should be considered as a diagnostic procedure which",
"    <strong>",
"     requires",
"    </strong>",
"    informed consent from the patient. There is no clear legal precedent which allows the physician to conduct a room search without the patient's consent and, if a search is performed without consent, there is the possibility of civil litigation for invasion of privacy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MUNCHAUSEN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of \"factitious illness\" includes a broad spectrum of diagnoses that have a similar psychiatric etiology, yet a wide range of presentations. It is to be emphasized that most patients with Munchausen syndrome do not present with factitious diarrhea and that not all causes of factitious diarrhea are examples of Munchausen syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In its milder forms, factitious illness can manifest merely as an exaggeration of physical symptoms in an effort to avoid responsibilities and gain sympathy (hypochondriasis).",
"     </li>",
"     <li>",
"      More serious presentations involve feigning illness to obtain drugs or avoid prosecution (malingering).",
"     </li>",
"     <li>",
"      Munchausen syndrome is the most extreme form, and is characterized by the feigning of severe illness to the point of undergoing multiple invasive procedures and operations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whereas the malingerer has obvious motives of which he or she is fully aware, the patient with Munchausen syndrome has no ulterior motive other than to assume the role of a patient. Although the actions of such patients are deliberate and purposeful, they are used to pursue goals that are involuntarily adopted and essentially hidden from the patient.",
"   </p>",
"   <p>",
"    In contrast to patients with factitious diarrhea, malingerers are frequently peripatetic men of lower socioeconomic class who have a lifelong pattern of social maladjustment, and who frequently are characterized as pathologic liars.",
"   </p>",
"   <p>",
"    Characteristic features of Munchausen syndrome include the simulation of a severe or dramatic illness requiring hospitalization, disease often produced by self-mutilation, multiple hospitalizations often at widely separated geographic locations, pathological lying, aggressive and evasive behavior, and premature self-discharge from the hospital against medical advice when confronted by the medical team.",
"   </p>",
"   <p>",
"    These patients are medically sophisticated, often showing evidence of prior treatment including extensive hospital records and often multiple surgical scars. Their behavior in the hospital is often disruptive, and they make frequent demands for analgesic medications without signs or symptoms of withdrawal when they are discontinued. Their symptoms shift from one organ system to another, and they tolerate painful, invasive procedures without complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gastroenterologist is most likely to encounter patients with this syndrome when they present with severe abdominal pain or other gastrointestinal complaints. One case report, for example, described a young former nurse who presented with severe abdominal pain and passage of blood and mucus rectally [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/17\">",
"     17",
"    </a>",
"    ]. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema showed severe inflammatory disease involving the rectum and sigmoid colon, which eventually led to colectomy with creation of an ileostomy. Subsequently, the patient was found to have been self-instilling caustic soda into the rectum.",
"   </p>",
"   <p>",
"    Munchausen syndrome by proxy (Polle Syndrome) involves the induction of factitious illness in children by their parents. There are multiple reports on this sad form of child abuse, several of which describe the induction of factitious diarrhea in children by administration of laxatives [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6246/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for patients with Munchausen syndrome is generally poor. It is more favorable in those who exhibit a depressive-masochistic personality disorder, and least favorable in those with a predominantly antisocial personality. Early psychiatric consultation should be requested, and if confrontation is to be undertaken at all, it should be done by the primary physician in a nonpunitive manner and without hostility. The most important aspect of management is early recognition of the disorder and avoidance of further invasive diagnostic or therapeutic interventions.",
"   </p>",
"   <p>",
"    Ultimately, there is a change in the overall therapeutic goal from cure of the simulated disease to coping with the Munchausen syndrome. Some patients may be allowed to use the factitious illness as a means for maintaining contact with the physician so that appropriate psychotherapy, behavior modification, and pharmacotherapy aimed at treating the psychiatric disorder may be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factitious diarrhea may be characterized by a true increase in stool volume, which is self-induced, or the creation of an apparent increase in stool volume by the addition of various substances to the stool. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surreptitious laxative abuse is the most frequent cause of factitious diarrhea. Laxative abuse often presents as watery diarrhea that is high in frequency and volume. The diarrhea is often associated with crampy abdominal pain. Lethargy and generalized weakness, malnutrition, dehydration, and electrolyte abnormalities may result. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the history, evaluation of the patient with suspected factitious diarrhea consists of stool analysis and attempted detection of chemical laxatives. Stool analysis consists of measurement of stool osmolality, and sodium, potassium, and magnesium concentrations. An osmolal gap (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/42/9890?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) indicates the presence of an unmeasured solute which can be due to laxatives containing magnesium,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      , lactose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      , or polyethylene glycol as the active ingredients.",
"      <br/>",
"      <br/>",
"      Colonoscopy may reveal melanois coli and a cathartic colon may be seen on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema. After organic causes of chronic diarrhea are ruled out, the following algorithm may be used to evaluate the cause of factitious diarrhea (",
"      <a class=\"graphic graphic_algorithm graphicRef58754 \" href=\"UTD.htm?31/20/32078\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation for factitious diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15548218\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to acknowledge Dr. Jodie Labowitz, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/1\">",
"      Bytzer P, Stokholm M, Andersen I, et al. Prevalence of surreptitious laxative abuse in patients with diarrhoea of uncertain origin: a cost benefit analysis of a screening procedure. Gut 1989; 30:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/2\">",
"      Neims DM, McNeill J, Giles TR, Todd F. Incidence of laxative abuse in community and bulimic populations: a descriptive review. Int J Eat Disord 1995; 17:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/3\">",
"      Ewe K, Karbach U. Factitious diarrhoea. Clin Gastroenterol 1986; 15:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/4\">",
"      Oster JR, Materson BJ, Rogers AI. Laxative abuse syndrome. Am J Gastroenterol 1980; 74:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/5\">",
"      Perez GO, Oster JR, Rogers A. Acid-base disturbances in gastrointestinal disease. Dig Dis Sci 1987; 32:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/6\">",
"      SCHWARTZ WB, RELMAN AS. Metabolic and renal studies in chronic potassium depletion resulting from overuse of laxatives. J Clin Invest 1953; 32:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/7\">",
"      Fine KD, Santa Ana CA, Fordtran JS. Diagnosis of magnesium-induced diarrhea. N Engl J Med 1991; 324:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/8\">",
"      Castelbaum AR, Donofrio PD, Walker FO, Troost BT. Laxative abuse causing hypermagnesemia, quadriparesis, and neuromuscular junction defect. Neurology 1989; 39:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/9\">",
"      Thomas PD, Forbes A, Green J, et al. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut 2003; 52 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/10\">",
"      Topazian M, Binder HJ. Brief report: factitious diarrhea detected by measurement of stool osmolality. N Engl J Med 1994; 330:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/11\">",
"      Pollock RC, Banks MR, Fairclough PD, Farthing MJ. Dilutional diarrhea: underdiagnosed and over-investigated. Eur J Gastroenterol Hepatol 2006; 12:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/12\">",
"      Shelton JH, Santa Ana CA, Thompson DR, et al. Factitious diarrhea induced by stimulant laxatives: accuracy of diagnosis by a clinical reference laboratory using thin layer chromatography. Clin Chem 2007; 53:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/13\">",
"      Ryan CM, Yarmush ML, Tompkins RG. Separation and quantitation of polyethylene glycols 400 and 3350 from human urine by high-performance liquid chromatography. J Pharm Sci 1992; 81:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/14\">",
"      Eisen T, Hotz J, Stolte M. [Diagnosis of factitious diarrhea (Munchausen syndrome) by colon biopsy]. Z Gastroenterol 1994; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/15\">",
"      Sekas G. The use and abuse of laxatives: Recognizing the abusive patient. Pract Gastroenterol 1987; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/16\">",
"      Folks DG, Freeman AM 3rd. M&uuml;nchausen's syndrome and other factitious illness. Psychiatr Clin North Am 1985; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6246/abstract/17\">",
"      ASHER R. Munchausen's syndrome. Lancet 1951; 1:339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2628 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6246=[""].join("\n");
var outline_f6_6_6246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CHARACTERISTICS OF FACTITIOUS DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION FOR FACTITIOUS DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stool analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Detection of chemical laxatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endoscopic or radiologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Room search",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MUNCHAUSEN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15548218\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2628|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/20/32078\" title=\"algorithm 1\">",
"      Evaluation for laxative abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2628|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/29/43474\" title=\"picture 1\">",
"      Melanosis coli Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/6/8299\" title=\"table 1\">",
"      Major causes of chronic secretory diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/2/2091\" title=\"table 2\">",
"      Laxative screening tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/42/9890?source=related_link\" title=\"calculator 1\">",
"      Calculator: Stool osmolal gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_6_6247="Nodular sarcoidosis";
var content_f6_6_6247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The histopathologic specimen shows a confluent mass of granulomas that have coalesced to form nodules several centimeters in size that are identifiable on chest radiograph. Multiple multinucleated giant cells are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6247=[""].join("\n");
var outline_f6_6_6247=null;
var title_f6_6_6248="Lipid abnormalities in patients with chronic kidney disease not requiring dialysis";
var content_f6_6_6248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6248/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6248/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6248/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/6/6248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in lipid metabolism occur in patients with all stages of chronic kidney disease (CKD) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The most common dyslipidemia in CKD and dialysis is hypertriglyceridemia, whereas the total cholesterol concentration can be normal or low, perhaps due in part to malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, the nephrotic syndrome is typically associated with hypercholesterolemia and hypertriglyceridemia.",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, epidemiology, and treatment of lipid abnormalities in CKD. The pathogenesis and significance of lipid abnormalities in nephrotic syndrome and following kidney transplantation, the association between CKD and coronary heart disease (CHD), and the management of lipids in patients with CKD who require dialysis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link&amp;anchor=H4#H4\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Lipid modification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of most lipid abnormalities in patients with CKD primary involves defective removal from the circulation. The diminished clearance of triglycerides, which can lead to hypertriglyceridemia, stems both from an alteration in the composition of circulating triglycerides (which become enriched with apolipoprotein C-III) and, perhaps later, from reductions in the activity of lipoprotein lipase and hepatic triglyceride lipase which are involved in triglyceride removal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Why lipoprotein lipase activity is reduced in CKD is not well understood but has been thought to reflect increased inhibitor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/4\">",
"     4",
"    </a>",
"    ]. The associated secondary hyperparathyroidism may play a contributory role, perhaps by increasing calcium accumulation within the cells in the liver and adipose tissue. Studies in humans and experimental animals with CKD suggest that parathyroidectomy can normalize serum triglyceride levels and hepatic lipase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In experimental animals, benefit can also be achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    by a similar mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/12\">",
"     12",
"    </a>",
"    ], although this has not been confirmed in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Secondary hyperparathyroidism and osteitis fibrosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another possible mechanism for hypertriglyceridemia in CKD is retention of a circulating inhibitor of lipoprotein lipase, such as pre-&szlig;-HDL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/13\">",
"     13",
"    </a>",
"    ]. Pre-&szlig;-HDL is a form of apolipoprotein A-I found in the non-lipoprotein fraction of normal plasma.",
"   </p>",
"   <p>",
"    Other findings that are more common in CKD patients compared with the general population include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower serum concentration of HDL cholesterol, which is thought to be due to impaired maturation of these particles. A possible contributing mechanism is downregulation of lecithin-cholesterol acyltransferase leading to reduced esterification of cholesterol that is incorporated into HDL [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated serum concentrations of lipoprotein(a), apolipoprotein(a), and postprandial chylomicron remnants. Increased serum lipoprotein(a) levels are due in part to diminished renal clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/15\">",
"       15",
"      </a>",
"      ], while the reasons behind the reduction in hepatic clearance of chylomicron remnants are not known.",
"     </li>",
"     <li>",
"      Increased oxidation of LDL cholesterol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the primary finding in CKD and dialysis is hypertriglyceridemia, as approximately 40 to 50 percent of patients with CKD have fasting triglyceride levels greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.26",
"    <span class=\"nowrap\">",
"     mmol/L).The",
"    </span>",
"    total serum cholesterol concentration is sometimes normal or low, perhaps due in part to malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hypertriglyceridemia that occurs in CKD may not significantly increase coronary risk, other changes may contribute to the accelerated atherosclerosis that is commonly seen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Triglycerides and atherosclerosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Chronic kidney disease as an independent risk factor for CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potentially pathogenic changes in serum lipids in patients with CKD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 to 30 percent have total serum cholesterol levels greater than 240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and 10 to 45 percent have LDL cholesterol levels greater than 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/1-7\">",
"       1-7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link&amp;anchor=H4#H4\">",
"       \"Screening guidelines for dyslipidemia\", section on 'Low density lipoprotein'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A modest decline in HDL-cholesterol is commonly observed, thereby raising the",
"      <span class=\"nowrap\">",
"       LDL/HDL",
"      </span>",
"      cholesterol ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/16\">",
"       16",
"      </a>",
"      ]. A cross-sectional study demonstrated that, compared with patients who had an estimated glomerular filtration rate (GFR) greater than 60 mL",
"      <span class=\"nowrap\">",
"       min/1.73",
"      </span>",
"      m2, lower levels of GFR were independently associated with decreased serum HDL [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link&amp;anchor=H7#H7\">",
"       \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'Low HDL-C as a risk factor for coronary heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated plasma levels of lipoprotein(a) are present in patients with CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Lipoprotein(a) is an LDL-like particle that contains an additional protein, apolipoprotein(a), and may be an independent risk factor for atherosclerosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link&amp;anchor=H5#H5\">",
"       \"Lipoprotein(a) and cardiovascular disease\", section on 'CVD risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Higher levels of post-prandial chylomicron remnants have been described in CKD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/20\">",
"       20",
"      </a>",
"      ]. Transient exposure of the vascular wall to these atherogenic particles may be deleterious. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H10#H10\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Exogenous pathway of lipid metabolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with CKD have an increase in the oxidative modification of LDL-cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H15#H15\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Lipoproteins and atherosclerosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8852139\">",
"    <span class=\"h2\">",
"     Association with mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, the serum total cholesterol concentration is a clear risk factor for coronary disease and death from cardiovascular disease, with the risk increasing progressively with higher values for serum total cholesterol. The concentrations of lipid fractions, such as low density lipoprotein (LDL) and high density lipoprotein (HDL), are also important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Lipids and lipoproteins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, studies in patients with CKD or end-stage renal disease are conflicting: some show a relation between higher serum cholesterol levels and mortality risk, especially among patients without signs of malnutrition and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]; some have found that low (not high) serum cholesterol values are associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/22,23,25,26\">",
"     22,23,25,26",
"    </a>",
"    ]; and some have found no association between lipid levels and mortality among patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The possibly worse prognosis with low serum cholesterol has been thought to reflect the adverse effect of malnutrition and chronic inflammation upon mortality, resulting in a paradoxical risk factor reversal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/26,30,31\">",
"     26,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CKD who do not require dialysis, we recommend initiation of a statin to prevent cardiovascular events. The use of lipid lowering therapy in patients treated with dialysis and issues related to muscle toxicity, the general safety of statins in patients with CKD, and the effects of statins on non-cardiovascular outcomes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link&amp;anchor=H4#H4\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Lipid modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link\">",
"     \"Statins and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cholesterol lowering with a statin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate CKD is associated with increased cardiovascular risk. As a result, consideration has been given to treating these patients as having a coronary heart disease (CHD) equivalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for the use of statins in patients with mild to moderate CKD comes from post-hoc sub-group analyses of randomized trials that were not intended to include patients with decreased kidney function. One randomized trial, the Study of Heart and Renal Protection (SHARP) trial, that specifically evaluated statin therapy to prevent major vascular events in patients with CKD and a meta-analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8355711\">",
"    <span class=\"h3\">",
"     Post-hoc analyses of CKD subgroups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of statins in lowering the rate of adverse outcomes, including cardiovascular death, among patients with CKD not requiring dialysis was assessed in a 2009 meta-analysis of 26 studies that enrolled 25,017 patients with stage 3 or 4 CKD (GFR between 15 and 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/32\">",
"     32",
"    </a>",
"    ]. Compared with placebo, statin therapy decreased the risk of all-cause mortality (relative risk [RR] 0.81, 95% CI 0.74-0.89, in 21 studies with 18,781 patients), cardiovascular death (RR 0.80, 95% CI 0.70-0.90, in 20 studies with 18,746 patients), and nonfatal cardiovascular events (RR 0.75, 95% CI 0.66-0.85, in 5 studies with 19,363 patients). Statin therapy was generally well tolerated.",
"   </p>",
"   <p>",
"    Similar findings were noted in a post-hoc subgroup analysis of the Treating to New Targets (TNT) trial, which was not included in the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/33\">",
"     33",
"    </a>",
"    ]. In this trial, 9656 of 10,001 patients had complete renal data, 3107 had an estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. All patients were assigned to either 80 or 10 mg per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    . At a median follow-up of five years, the patients assigned to 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of atorvastatin had a significant 4.1 percent absolute reduction in risk of cardiovascular events, compared with patients who received 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of atorvastatin (9.3 versus 13.4 percent). The absolute risk reduction was only 1.4 percent in patients with normal kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'TNT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8853471\">",
"    <span class=\"h3\">",
"     SHARP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SHARP trial evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    compared with placebo in lowering cardiovascular morbidity in patients with CKD, approximately one-third of whom required maintenance dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/34\">",
"     34",
"    </a>",
"    ]. The results dealing with the 3023 dialysis patients enrolled in SHARP, along with the findings from two other large trials of statin therapy in dialysis patients (4-D and AURORA) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link&amp;anchor=H5#H5\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Trials of statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Originally, patients were randomly allocated to three treatment arms: a combination pill containing 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    and 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    ; 20 mg of simvastatin only; or placebo. After one year of follow-up, however, the patients in the simvastatin only arm were reassigned to receive either the combination pill or placebo; this re-randomization of the simvastatin only group was prespecified to occur at one year if adverse events were no greater with the combination of simvastatin and ezetimibe than with simvastatin alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SHARP included 6247 patients with CKD who were not treated with maintenance dialysis. The mean age of this non-dialysis group was 62 years; the mean estimated GFR was 27",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, 23 percent had diabetes, and by design none had a history of myocardial infarction or coronary revascularization. During a median follow-up of 4.9 years,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"      simvastatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"      ezetimibe",
"     </a>",
"    </span>",
"    lowered the incidence of the primary endpoint of coronary death, myocardial infarction, ischemic stroke, or any revascularization procedure (9.5 versus 11.9 percent).",
"   </p>",
"   <p>",
"    Results for the individual components of this composite endpoint were presented only for the entire study population (combining dialysis and non-dialysis patients). Among the entire population, the benefit of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"      simvastatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"      ezetimibe",
"     </a>",
"    </span>",
"    appeared to be driven by a 1.0 percent absolute reduction in the risk of ischemic stroke and a 1.5 percent absolute reduction in the risk of needing a revascularization procedure. There was no significant difference in the rate of progression to end-stage renal disease. Discontinuation of the study medication due to myalgias was significantly more common with",
"    <span class=\"nowrap\">",
"     simvastatin/ezetimibe",
"    </span>",
"    therapy (1.1 versus 0.6 percent), but the rates of other adverse effects were similar between the treatment and placebo groups.",
"   </p>",
"   <p>",
"    Numerous statin trials in high-risk populations demonstrate reductions in the risk of cardiovascular events proportional to the degree of reduction in LDL-cholesterol. The benefit in SHARP in relation to the fall in LDL-cholesterol was similar to that in the other trials. It is not clear if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    contributed to the clinical benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H877999749\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses have been performed of randomized controlled trials that examined a benefit of lipid-lowering agents (including statins and statins plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    in two trials) among patients with all stages of CKD, including those on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study lipid-lowering agents were associated with a decreased risk for cardiac mortality (six trials, RR 0.82, 95% CI 0.74-0.91), cardiovascular events including revascularization (nine trials, RR 0.78, 95% CI 0.71&ndash;0.86) and myocardial infarction (nine trials, RR 0.74, 95% CI 0.67-0.81) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/35\">",
"       35",
"      </a>",
"      ]. Lipid-lowering agents were associated with decreased all-cause mortality (RR 0.91, 95% CI 0.83&ndash;0.99) but there was significant heterogeneity between studies. Kidney outcomes were not improved by lipid-lowering agents. Interpretation of this meta-analysis is limited by the inclusion of patients with all stages of CKD, including those on dialysis and transplant recipients.",
"     </li>",
"     <li>",
"      A second meta-analysis showed a reduction in all-cause mortality (RR 0.81, 95%CI 0.74-0.88), cardiovascular mortality (RR 0.78 95% CI 0.68-0.89), and cardiovascular events (RR 0.76, 95% CI 0.73-0.80) among patients not receiving dialysis but no benefit among patients on dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/36\">",
"       36",
"      </a>",
"      ]. The effect of statins among transplant recipients was not clear. Results among dialysis patients and transplant recipients are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link&amp;anchor=H878000148#H878000148\">",
"       \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Meta-analyses'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link&amp;anchor=H10#H10\">",
"       \"Lipid abnormalities after renal transplantation\", section on 'Treatment of dyslipidemias'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339500\">",
"    <span class=\"h3\">",
"     Statin therapy versus LDL goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current recommendations concerning the goals of lipid management with statin therapy in patients with CKD are largely based upon extrapolation from the CHD trials. Given the evidence that CKD is a strong and independent risk factor for CHD, CKD is considered a CHD risk equivalent. As a result, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for managing dyslipidemias in CKD suggest targeting an LDL cholesterol level below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with CKD.",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines that were updated in 2006 can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H6#H6\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'CKD as a CHD risk equivalent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative strategy would be to dose statins based upon the doses that were beneficial in clinical trials, disregarding the achieved LDL cholesterol. This argument is based upon the reality that lipid lowering with agents other than statins have not been shown to significantly reduce the risk of death or cardiovascular morbidity. Furthermore, the LDL cholesterol goals are derived from post-hoc, observational, analyses of randomized trials which used particular doses of statins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H7#H7\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Statin dose versus goal LDL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related issue is whether the cardiovascular benefit of statins is due in part to their pleiotropic effects that are independent of lipid-lowering. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240928130\">",
"    <span class=\"h2\">",
"     Triglyceride lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary modification may be helpful for the hypertriglyceridemia of CKD. Among lipid-lowering drugs, the fibric acids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , are most effective in lowering serum triglyceride levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VA-HIT trial evaluated the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    in patients with established CHD and an HDL-cholesterol of less than 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    There were 1046 men who had mild to moderate renal dysfunction, defined as an estimated glomerular filtration rate between 30 and 75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6248/abstract/38\">",
"     38",
"    </a>",
"    ]. Among these patients, gemfibrozil therapy significantly lowered the risk of the primary endpoint of coronary death and nonfatal myocardial infarction (18.2 versus 24.3 percent, hazard ratio [HR] 0.73, 95% CI 0.56-0.96). However, gemfibrozil therapy had no effect on total mortality (HR 1.03) and was associated with a significant decline in renal function. In addition, fibrates are associated with an increased risk of rhabdomyolysis in patients with CKD, particularly those who are also treated with a statin.",
"   </p>",
"   <p>",
"    There is no consensus among the author and reviewers of this topic as to whether fibrate therapy should or should not be used in CKD patients with hypertriglyceridemia. The strategies for management of hypertriglyceridemia in patients without CKD can probably be applied to patients with CKD. These management strategies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H723637349#H723637349\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In view of the benefits provided by statin therapy described above, the potential harm associated with the addition of fibrate therapy to specifically lower triglycerides may outweigh any possible reduction in cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities in lipid metabolism occur in patients with all stages of chronic kidney disease (CKD). The most common dyslipidemia in CKD patients is hypertriglyceridemia, whereas the total cholesterol concentration can be normal or low, perhaps due in part to malnutrition. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of most lipid abnormalities in patients with CKD primary involves defective removal from the circulation. The common occurrence of low HDL cholesterol levels in CKD patients, on the other hand, is thought to be due to impaired maturation of these particles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipid abnormalities found in patients with CKD that may contribute to the higher risk of cardiovascular disease in this population include elevated LDL cholesterol levels, lower HDL cholesterol concentrations, elevated levels of lipoprotein(a), higher levels of post-prandial chylomicron remnants, and increased oxidative modification of LDL cholesterol. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some studies in patients with CKD show a relation between higher cholesterol levels and mortality risk, while other studies have found that low (not high) serum total cholesterol values are associated with increased mortality. This may reflect the profound adverse effect of malnutrition and chronic inflammation upon mortality, resulting in a paradoxical risk factor reversal. (See",
"      <a class=\"local\" href=\"#H8852139\">",
"       'Association with mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CKD who do not require dialysis and who do not have another indication for a statin such as established CHD, we recommend initiation of a statin (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This recommendation is based upon evidence from randomized trials demonstrating that statin therapy lowers the risk of cardiovascular disease events in patients with CKD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cholesterol lowering with a statin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In CKD patients who do not require dialysis and who are able to tolerate statins, we suggest using a statin dose that is similar to the dose that has shown efficacy in randomized trials (eg, 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      in SHARP) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although current guidelines suggest targeting an LDL cholesterol level below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      our approach is to treat regardless of the initial LDL cholesterol level. (See",
"      <a class=\"local\" href=\"#H339500\">",
"       'Statin therapy versus LDL goals'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H10#H10\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Putting the evidence together'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug therapy to lower serum triglycerides in patients with CKD is of uncertain overall benefit. While fibrate therapy appears to lower the risk of cardiovascular events in patients with CKD who have known CHD, they appear to have no effect of total mortality, may worsen renal function, and, particularly in patients also treated with a statin, lead to muscle injury. In view of the benefits provided by statin therapy, the potential harm associated with the addition of fibrate therapy to specifically lower triglycerides may outweigh any possible reduction in cardiovascular risk. There is no consensus among the author and reviewers of this topic as to whether fibrate therapy should or should not be used in CKD patients with hypertriglyceridemia. (See",
"      <a class=\"local\" href=\"#H240928130\">",
"       'Triglyceride lowering'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/1\">",
"      Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/2\">",
"      Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/3\">",
"      Sent&iacute; M, Romero R, Pedro-Botet J, et al. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/4\">",
"      Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/5\">",
"      Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/6\">",
"      Afzali B, Haydar AA, Vinen K, Goldsmith DJ. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/7\">",
"      Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/8\">",
"      Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/9\">",
"      Arnadottir M, Thysell H, Dallongeville J, et al. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 1995; 48:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/10\">",
"      Lacour B, Roullet JB, Liagre AM, et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986; 8:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/11\">",
"      Liang K, Oveisi F, Vaziri ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998; 53:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/12\">",
"      Akmal M, Perkins S, Kasim SE, et al. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis 1993; 22:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/13\">",
"      Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/14\">",
"      Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens 2009; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/15\">",
"      Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/16\">",
"      Seres DS, Strain GW, Hashim SA, et al. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/17\">",
"      Lo JC, Go AS, Chandra M, et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 2007; 50:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/18\">",
"      Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/19\">",
"      Kuboyama M, Ageta M, Ishihara T, et al. Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb 2003; 10:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/20\">",
"      Wilson DE, Chan IF, Cheung AK, et al. Retinyl ester retention in chronic renal failure. Further evidence for a defect in chylomicron remnant metabolism. Atherosclerosis 1985; 57:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/21\">",
"      Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/22\">",
"      Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/23\">",
"      Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/24\">",
"      Contreras G, Hu B, Astor BC, et al. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 2010; 21:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/25\">",
"      Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/26\">",
"      Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/27\">",
"      Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007; 18:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/28\">",
"      Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/29\">",
"      Chawla V, Greene T, Beck GJ, et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/30\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/31\">",
"      Degoulet P, Legrain M, R&eacute;ach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/32\">",
"      Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; :CD007784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/33\">",
"      Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/34\">",
"      Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/35\">",
"      Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/36\">",
"      Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/37\">",
"      Nishizawa Y, Shoji T, Nishitani H, et al. Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int 1993; 44:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6248/abstract/38\">",
"      Tonelli M, Collins D, Robins S, et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66:1123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7204 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6248=[""].join("\n");
var outline_f6_6_6248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8852139\">",
"      Association with mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cholesterol lowering with a statin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8355711\">",
"      - Post-hoc analyses of CKD subgroups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8853471\">",
"      - SHARP trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H877999749\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H339500\">",
"      - Statin therapy versus LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H240928130\">",
"      Triglyceride lowering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_6_6249="Coronary artery with dissection";
var content_f6_6_6249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Coronary artery with dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross sectional view of the coronary artery, a dissection flap is separated from the coronary artery wall and protruding into the lumen (arrow). (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.",
"    <div class=\"footnotes\">",
"     OCT: St. Jude/Lightlab Imaging C7XR.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6249=[""].join("\n");
var outline_f6_6_6249=null;
var title_f6_6_6250="Clinical significance and molecular characteristics of common hepatitis B virus variants";
var content_f6_6_6250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical significance and molecular characteristics of common hepatitis B virus variants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Chi-Jen Chu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/6/6250/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/6/6250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral DNA and especially RNA genomes are inherently variable due to errors introduced during replication. These errors are in the range of 1 mutation in 1,000 to 100,000 nucleotides per replication cycle for RNA viruses, and approximately 1 mutation in 100,000,000 nucleotides per replication cycle for DNA viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The higher mutation rate among RNA viruses is related to the lack of proofreading functions of RNA polymerases and reverse transcriptases. As a result, mutations in viral genomic sequences are generated naturally during viral replication and should be viewed as a normal biological event.",
"   </p>",
"   <p>",
"    Hepatitis B virus (HBV), a member of the Hepadnaviridae family, replicates asymmetrically via reverse transcription of an RNA intermediate, making it prone to mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/3\">",
"     3",
"    </a>",
"    ]. The estimated mutation rate of the hepadnavirus genome is about 2 x 10(4) base",
"    <span class=\"nowrap\">",
"     substitutions/site/year,",
"    </span>",
"    about 100 times higher than that of other DNA viruses but about 100 to 1,000 times lower than that of other RNA viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/4\">",
"     4",
"    </a>",
"    ]. Although mutations can occur randomly along the HBV genome, the overlapping open reading frames limit the number and location of viable mutations. Because chronic HBV infection frequently persists for decades, many variants may exist within the same host at any given time and each variant may have multiple base changes.",
"   </p>",
"   <p>",
"    Selection by the host for the fittest variant occurs after the random mutation process. Fitness may be defined at the cellular level (viruses that replicate most efficiently in a cell type will predominate) or at the extra-cellular level (viruses that avoid immune elimination will become dominant) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, the accumulation of viral variants depends upon the rate at which the variants are generated and the advantage they confer to the virus.",
"   </p>",
"   <p>",
"    The genetically different viral species concomitantly present in a single cell or in a single individual are termed quasi-species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/1\">",
"     1",
"    </a>",
"    ]. Interpretation of the clinical significance of HBV mutations is complicated by the lack of standardized nomenclature, differences in sensitivities of assays used in their detection, and the presence of mutations in more than one region of the HBV genome even in the same species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Despite these difficulties, in vivo analyses of naturally occurring viral variants and in vitro mutagenesis studies have identified some mutations that have a role in viral latency, pathogenesis of liver disease, immune escape, and resistance to antiviral therapy. This topic review will summarize the clinical relevance and molecular characteristics of common HBV variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRECORE AND CORE PROMOTER VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     precore/core",
"    </span>",
"    region of the HBV genome encodes the nucleocapsid protein (HBcAg) and HBeAg [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The core open reading frame has two transcripts with heterogeneous 5' ends and two in-phase initiation codons. HBeAg is translated from the precore mRNA, producing a precursor polypeptide comprising the precore and the entire core region. The precore polypeptide is translocated into the endoplasmic reticulum by a signal peptide. Cleavage of the amino and carboxy termini results in a secretory protein, HBeAg. HBcAg is translated from the pregenomic RNA. Both HBcAg and HBeAg contain B- and T-cell epitopes, of which some are shared. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secretion of HBeAg can be modulated at both transcriptional and translational levels. Transcription of the precore and pregenomic RNAs is under the control of regulatory elements including the basic core promoter and the core upstream regulatory sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/10\">",
"     10",
"    </a>",
"    ]. Mutations in these domains decrease precore mRNA transcription and HBeAg synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. At the translational level, mutations within the precore region can block the translation of the precore protein and hence HBeAg. The most common mutation in the precore region is a point mutation (G to A switch at nucleotide 1896), which changes codon 28 from tryptophan to a stop [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Because this mutation occurs upstream of the core start codon and because HBcAg is translated from a different transcript, nucleocapsid production is not interrupted.",
"   </p>",
"   <p>",
"    The biological role of HBeAg in the HBV replication cycle is uncertain. Expression of HBeAg is nonessential for virus replication in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/16\">",
"     16",
"    </a>",
"    ] and in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/17\">",
"     17",
"    </a>",
"    ]. HBeAg may act as a tolerogen or a target for immune response. In utero exposure to HBeAg can induce immune tolerance in newborn mice [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/18\">",
"     18",
"    </a>",
"    ]. Perinatal transmission of HBV from HBeAg-positive mothers results in chronic HBV infection in the majority of babies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, HBeAg appears to modulate the host's immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Precore variants that do not produce HBeAg may be selected because they can evade immune clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Precore variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common precore variant has a point mutation at nucleotide 1896, creating a stop at codon 28 (G1896A, eW28X). This mutation is accompanied by another point mutation (G to A) at nucleotide 1899 in some patients. In vitro studies have demonstrated that precore protein can inhibit HBV replication, suggesting that precore stop codon variants may enhance viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, patients with HBeAg-negative chronic hepatitis tend to have lower HBV DNA levels compared to those with HBeAg-positive chronic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/15,27\">",
"     15,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other naturally occurring mutations in the precore region include point mutations leading to initiation failure as well as deletions and insertions of nucleotides inducing frameshifts. In addition to the eW28X stop codon mutation, the most frequent precore mutations that can abrogate HBeAg production are point mutations in the start codon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study involving 17 centers in the United States, precore variants were found in 27 percent of patients with chronic HBV infection, being significantly more common among the HBeAg negative than the HBeAg positive patients (38 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/30\">",
"     30",
"    </a>",
"    ]. These data indicate that precore variant is not rare in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Core promoter variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common core promoter variant involves a dual mutation A1762T, G1764A (TA change). A number of mutations have been found to occur together with the TA change, including changes at nucleotide 1653, 1753 to 1757, and the dual mutation C1766T G1768A. The latter mutations are most often found in patients with fulminant hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletions within the basic core promoter, which overlap with the X gene, have been found to occur in asymptomatic carriers, patients with chronic hepatitis B or HCC, and individuals with no HBV serologic markers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Infection with these deletion variants is usually associated with low HBV DNA levels.",
"   </p>",
"   <p>",
"    In the nationwide United States study, the dual core promoter variants were found in 44 percent of patients with chronic HBV infection, being significantly more common among the HBeAg negative than the HBeAg positive patients (51 versus 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to direct sequencing, several methods can be used to detect precore and core promoter variants including RFLP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], line probe assay [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], ligase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/39\">",
"     39",
"    </a>",
"    ], and colorimetric point mutation assay [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/40\">",
"     40",
"    </a>",
"    ]. Some methods such as line probe assay and RFLP are more sensitive in detecting minor variants than direct sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The controversies surrounding the clinical significance of precore and core promoter variants is related to the heterogeneity of the study population, sensitivity of the methods used to detect these variants, and to the format in which results are reported. Some studies particularly those that rely on less sensitive methods such as direct sequencing only report the presence of variants when the variant is present as the predominant sequence while other studies report the presence of variants when the variant is detected as a minor sequence in a mixed population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relationship to HBeAg status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precore variants have been detected mainly in patients who are HBeAg negative but they can also be found in some HBeAg positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/14,15,30,41\">",
"     14,15,30,41",
"    </a>",
"    ]. HBeAg positive patients with precore variants are more likely to undergo spontaneous HBeAg seroconversion and to do so earlier than those with wild type precore sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These findings are in accordance with the observation that precore variants that prevent HBeAg production are selected around the time of HBeAg clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/14,15,41\">",
"     14,15,41",
"    </a>",
"    ]. However, not all HBeAg seroconversion requires the selection of precore mutations.",
"   </p>",
"   <p>",
"    Unlike precore variants, core promoter variants can be detected in similar proportions of HBeAg-negative and HBeAg-positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/30,44,45\">",
"     30,44,45",
"    </a>",
"    ]. One study demonstrated that emergence of the dual core promoter (T to A) change was more common among HBeAg-positive patients who subsequently seroconverted compared to those who remained HBeAg positive, indicating that the selection of core promoter variants may play a role in HBeAg clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/46\">",
"     46",
"    </a>",
"    ]. This study also found that core promoter variants could be detected earlier than precore variants in patients who cleared HBeAg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Relationship to HBeAg negative chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seroconversion from HBeAg to anti-HBe is usually accompanied by decreased levels of HBV replication and remission of liver disease. However, some HBeAg-negative patients continue to have high HBV DNA levels and active liver disease, so-called HBeAg-negative chronic hepatitis B (e-CHB). Many of these patients harbor HBV variants in the precore or core promoter region [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/13-15,41,47,48\">",
"     13-15,41,47,48",
"    </a>",
"    ], although some continue to have low levels of wild type HBV.",
"   </p>",
"   <p>",
"    The phenomenon of e-CHB can be defined as patients who fulfill the following criteria: (1) HBsAg positive, (2) HBeAg negative, (3) Have serum HBV DNA &gt;10(4)",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    and (4) Persistent or intermittent elevation in aminotransferase levels that cannot be attributed to other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are clinical differences between HBeAg-positive and HBeAg-negative chronic hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients with HBeAg-negative chronic hepatitis B tend to have lower serum HBV DNA levels and are more likely to run a fluctuating course characterized by persistently elevated or fluctuating serum aminotransferase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/15,27,50\">",
"     15,27,50",
"    </a>",
"    ]. Patients with HBeAg-negative chronic hepatitis B also tend to be older and have more advanced liver disease because they are in a later phase of chronic HBV infection.",
"   </p>",
"   <p>",
"    Patients with e-CHB have been reported in all parts of the world but are more common in Mediterranean countries and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/45,51-54\">",
"     45,51-54",
"    </a>",
"    ]. The worldwide prevalence of e-CHB is not known precisely because large population-based studies have not been performed. However, it has been estimated to account for 7 to 30 percent of patients with chronic hepatitis B worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/55\">",
"     55",
"    </a>",
"    ]. The ratio of e-CHB to HBeAg-positive CHB has increased worldwide because of the decline in new cases of HBV infection secondary to implementation of HBV vaccination and aging of previously infected persons. &nbsp;",
"   </p>",
"   <p>",
"    The geographical differences in the relative frequency of HBeAg positive versus HBeAg negative chronic hepatitis B are largely related to differences in the distribution of HBV genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .) The most common HBV variant associated with e-CHB, G1896A, is usually found in association with HBV genotype D (which is prevalent in the Mediterranean basin) and is rarely detected in association with genotype A (which is prevalent in the United States and North-West Europe). Different genotypes also account for the heterogeneity of e-CHB around the world. As an example, initial studies from the Mediterranean basin reported that more than 90 percent of patients with e-CHB were infected with the precore stop codon variant (G1896A) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/51\">",
"     51",
"    </a>",
"    ]. However, studies in Hong Kong found that only 40 percent of patients with e-CHB had the precore variant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/45\">",
"     45",
"    </a>",
"    ]. A higher prevalence of the precore variant among patients with e-CHB in the Mediterranean basin is related to the predominance of HBV genotype D in this region, while HBV genotypes B and C prevail in Asia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggested that precore and core promoter variants were associated with more severe liver disease and hepatocellular carcinoma (HCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/13,15,59-62\">",
"     13,15,59-62",
"    </a>",
"    ]. However, these variants have also been detected in inactive carriers and patients with minimal liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/40,44,52,56\">",
"     40,44,52,56",
"    </a>",
"    ]. Furthermore, precore and core promoter variants had no impact on pre- and post-liver transplant outcomes in a study from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/63\">",
"     63",
"    </a>",
"    ]. It is possible that host immune response and mutations in other regions of the HBV genome may be involved in the pathogenesis of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recently, there are increasing data to support an association between core promoter variants and more severe liver disease. A study from Hong Kong found patients with core promoter mutation tended to have higher hepatic necroinflammation score [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/65\">",
"     65",
"    </a>",
"    ]. The same group reported the prevalence of core promoter mutations was higher among chronic hepatitis B patients who developed complications of cirrhosis and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study from Taiwan involving 250 chronic hepatitis B infected patients found that the prevalence of core promoter variants increased from 3 percent among inactive carriers to 64 percent among patients with HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/68\">",
"     68",
"    </a>",
"    ]. When controlling for other potential confounders such as gender, age, genotype and presence of cirrhosis, the core promoter variants (A1762T, G1764A) was still significantly associated with the development of HCC (odds ratio: 10.6). A longitudinal study from Taiwan demonstrated that persistence of core promoter mutations accumulated over time before the diagnosis of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/69\">",
"     69",
"    </a>",
"    ]. Another study from the United States reported that patients with core promoter variants were more likely to have hepatic decompensation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major drawback of the above studies is that the conclusions were based on cross-sectional analyses. As a result, large-scale longitudinal studies with consideration of other host and viral confounders are needed to confirm the relationship between core promoter variants and advanced liver disease. One such study included 2762 Taiwanese men and women with chronic HBV followed between 1991 and 2004 (for a total of 33,747 person years), during which a total of 153 incident cases of HCC were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/71\">",
"     71",
"    </a>",
"    ]. After adjusting for baseline HBV DNA levels, sex, and age of recruitment, the basal core promoter variant",
"    <span class=\"nowrap\">",
"     A1762T/G1764Aand",
"    </span>",
"    genotype C were predictors of increased risk of HCC, while the precore variant G1896A was associated with a lower risk of HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fulminant hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precore and core promoter variants have been described in association with fulminant hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/7,72-75\">",
"     7,72-75",
"    </a>",
"    ]. It has been suggested that these variants result in a fulminant course because of enhanced HBV replication or a more aggressive immune response. However, in some studies, these variants were also detected in asymptomatic source patients who led to the outbreak of fulminant hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/76\">",
"     76",
"    </a>",
"    ]. The mechanism by which precore variants cause fulminant hepatitis in the new host but an inactive liver disease in the original host is unclear. It is possible that de novo infection with precore variants elicits a more aggressive immune response while precore variants that are selected during the course of infection may escape immune clearance and are associated with less active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serum quantitative HBV DNA levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data on the relationship between",
"    <span class=\"nowrap\">",
"     precore/core",
"    </span>",
"    promoter variants and serum quantitative HBV DNA levels. The most comprehensive study was done in the United States and involved a total of 694 consecutive chronic HBV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/70\">",
"     70",
"    </a>",
"    ]. HBeAg-positive patients with core promoter variant had significantly lower serum HBV DNA levels compared to those with wild type sequence in the core promoter region. A possible explanation was the selection of core promoter variants during the process of immune clearance. By contrast, precore",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    core promoter variants were associated with higher serum HBV DNA levels than wild type sequence in HBeAg-negative patients, which may be because",
"    <span class=\"nowrap\">",
"     precore/core",
"    </span>",
"    promoter variants can evade the host immune response and can thus maintain higher levels of HBV replication. This observation has been confirmed by subsequent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interferon (IFN) therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have found that interferon therapy is associated with a low rate of sustained response among patients with e-CHB [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. These studies suggested that a longer duration of treatment (&gt;12 months) was necessary to decrease the rate of post-treatment relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relatively few studies have evaluated the relationship between precore and core promoter mutations and response to interferon therapy and results have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/42,43,82-85\">",
"     42,43,82-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBeAg-positive patients: Some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/42,43\">",
"       42,43",
"      </a>",
"      ] found that patients who were HBeAg positive with precore variant were more likely to achieve HBeAg",
"      <span class=\"nowrap\">",
"       loss/seroconversion",
"      </span>",
"      with IFN therapy while disparate results have been reported by others [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/82-84,86\">",
"       82-84,86",
"      </a>",
"      ]. Whether the conflicting results could be accounted for by differences in HBV genotypes or baseline HBV DNA levels is unknown.",
"     </li>",
"     <li>",
"      HBeAg-negative patients: One study from Italy showed that patients with exclusively or predominantly precore variant had a higher rate of relapse after initial response to IFN [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/79\">",
"       79",
"      </a>",
"      ]. A study from Germany found that responders to IFN therapy had significantly fewer mutations in the basic core promoter region compared with non-responders [",
"      <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nucleoside analogue therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with e-CHB relapse after one year of nucleoside analogue treatment (see appropriate topic reviews). As with IFN, longer duration of treatment is needed to maintain viral suppression.",
"   </p>",
"   <p>",
"    There is very little information on the correlation between precore and core promoter mutations and response or resistance during nucleoside analogue therapy. Clinical studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    show that nucleoside analogues have similar potency in HBeAg-positive and in HBeAg-negative patients. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    One in vitro study found that the precore mutation did not significantly affect sensitivities to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/87\">",
"     87",
"    </a>",
"    ]. Preliminary results of one study suggested that core promoter (TA change), but not precore (G1896A) mutation, was associated with the selection of lamivudine-resistant mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition, precore variants may be replaced by wild-type sequences and reappearance of HBeAg when lamivudine resistant mutants emerge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study showed that there were interactions between",
"    <span class=\"nowrap\">",
"     precore/core",
"    </span>",
"    promoter variants and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/89\">",
"     89",
"    </a>",
"    ]. Precore variant may compensate for the replication inefficiency of lamivudine-resistant mutants whereas core promoter variants increased viral replication levels to above the wild type baseline values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of the biologic and pathogenic significance of precore and core promoter variants should be made cautiously because many factors such as HBV genotype, viral quasispecies, mutations in other regions of the HBV genome, host immune response, and sensitivity of detection methods can influence the results. Testing precore and core promoter variants especially in patients suspected for e-CHB can help further characterize the patient but these tests are not routinely indicated for clinical management because the precise role of these variants in predicting the severity of liver disease or response to antiviral therapy remain unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRE-S/S VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major B-cell neutralizing epitopes of HBsAg reside in the \"a\" determinant region located at amino acid positions 124 to 149 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Antibodies to the \"a\" determinant confer protection against all serotypes of HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/92\">",
"     92",
"    </a>",
"    ]. The pre-S and S regions of the HBV genome also contain putative HLA class I-restricted cytotoxic T lymphocyte (CTL) epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/93\">",
"     93",
"    </a>",
"    ]. Mutations involving T or B cell epitopes in the pre-S and S regions may result in immune escape mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/94\">",
"     94",
"    </a>",
"    ]. In addition, mutations in the pre-S region may affect the secretion of small S protein. Clinically significant",
"    <span class=\"nowrap\">",
"     pre-S/S",
"    </span>",
"    variants will be discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vaccine-escape mutants",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV S gene mutants have been described in infants who were infected with hepatitis B despite an adequate anti-HBs response to hepatitis B vaccination. These mutations have been observed in many parts of the world, including Italy, Singapore, Taiwan, Japan, China, and Africa. The most common mutation involves glycine to arginine substitution at codon 145 (G145R) in the \"a\" determinant of HBsAg. In vitro studies confirmed that HBsAg with G145R mutation had decreased binding to hepatitis B surface antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/95\">",
"     95",
"    </a>",
"    ]. Other mutations involving amino acids 126, 129, and 141 have also been reported among vaccinees but the clinical significance of these mutants is not well documented.",
"   </p>",
"   <p>",
"    Most reports found that the vaccine-related HBV S mutants were not detected in the maternal carriers, suggesting that the mutations were selected by vaccine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HBIG. However, a few reports suggested that these mutants were transmitted from the mothers to the babies. One study reported horizontal transmission of G145R mutation to intrafamilial members [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study from Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/97\">",
"     97",
"    </a>",
"    ] found that the prevalence of HBV S mutants among HBsAg positive children increased after the introduction of universal vaccination, from 7.8 percent in 1984 to 25 percent in 1994, and about 23 percent in 1999. However, the carrier rate among Taiwanese children decreased from 9.8 to 0.7 percent in the same period. These data suggest that the emergence of vaccine escape mutants has not diminished the efficacy of HBV vaccines but continued monitoring is necessary to determine if the prevalence of these mutants in the general population will increase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immunoprophylaxis failure in orthotopic liver transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV reinfection in patients receiving maintenance HBIG immunoprophylaxis may be due to inadequate dosing or to the emergence of mutant virus that can escape neutralization. Several studies reported the detection of S mutants in patients who developed recurrent hepatitis B after liver transplantation despite HBIG prophylaxis. As with vaccine failure, G145R is the most common mutation. One study found significant correlation between these mutants and the duration of HBIG therapy and reversion of the mutation to wild type sequence after withdrawal of HBIG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Viral persistence in HBsAg-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of HBsAg usually indicates clearance of HBV particles. However, low levels of HBV DNA can be detected in serum, liver, and polymorphonuclear cells from some HBsAg-negative individuals using PCR assays [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/98\">",
"     98",
"    </a>",
"    ]. In most instances of occult HBV infection (HBsAg negative but HBV DNA positive by PCR), HBV DNA is present in very low concentrations with sub-detectable amounts of HBsAg. However, in rare instances, mutations in the HBV genome down-regulate S gene expression or produce aberrant surface proteins. As a result, HBsAg is not detectable by conventional serologic assays [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. Occult HBV infection may have an impact on blood transfusion, organ transplantation, diagnosis of cryptogenic liver disease, and HCC development [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POLYMERASE GENE MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HBV DNA polymerase gene consists of four distinct regions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/104\">",
"     104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A primer involved in priming of reverse transcription",
"     </li>",
"     <li>",
"      A spacer with no known function",
"     </li>",
"     <li>",
"      A reverse",
"      <span class=\"nowrap\">",
"       transcriptase/DNA",
"      </span>",
"      polymerase which is responsible for reverse transcription of the pregenomic RNA into the first (-) strand HBV DNA and for synthesis of the second (+) strand HBV DNA",
"     </li>",
"     <li>",
"      An RNAse H, which removes the RNA template",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reverse",
"    <span class=\"nowrap\">",
"     transcriptase/DNA",
"    </span>",
"    polymerase region has five conserved domains: A, B, C, D, E. Domains A, C, and D are involved in nucleoside triphosphate binding and catalysis, while domains B and E participate in the positioning of the RNA template and the primer, relative to the catalytic site [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. The putative catalytic domain is believed to reside in the tyrosine-methionine-aspartate-aspartate (YMDD) locus in domain C. This locus is conserved in all viral reverse transcriptases as well as in all isolates of hepadnaviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/104\">",
"     104",
"    </a>",
"    ]. Polymerase gene mutations that are associated with antiviral resistance can arise spontaneously but are rarely detected unless they have been selected by exposure to oral nucleos(t)ide analogues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     X GENE VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The X region is crucial for the replication and expression of HBV because the X protein regulates HBV replication through activating and regulating viral and cellular genes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. The X region overlaps the core promoter, enhancer II, and two direct repeats that are involved in regulating precore and pregenomic mRNA transcription. HBx protein is believed to be important in hepatic carcinogenesis. Several studies reported that mutations affecting codons 130 and 131 of the X gene are more common in patients with HCC than in patients with chronic hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/61,62,109\">",
"     61,62,109",
"    </a>",
"    ]. However, these mutations correspond to the dual core promoter mutations A1762T and G1764A.",
"   </p>",
"   <p>",
"    Although many studies have shown a convincing relationship between core promoter variants and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/67-69\">",
"     67-69",
"    </a>",
"    ], it is unclear if core promoter variant is directly involved in the process of carcinogenesis or the increased risk of HCC is related to more active and rapidly progressive liver disease. Because of the association between core promoter variants and HBV genotype C, and more active hepatic necroinflammation, careful analysis is needed to determine if core promoter mutation is independently related to HCC development. A prospective cohort study from Taiwan found that core promoter but not precore mutation was associated with an increased risk of HCC and the association was independent of HBV genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?6/6/6250/abstract/71\">",
"     71",
"    </a>",
"    ]. However, more studies are needed to clarify these associations. Whether X gene mutations that are unrelated to the common dual core promoter mutation increase the risk of HCC also needs further clarifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97394206\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because chronic hepatitis B virus (HBV) infection frequently persists for decades, many variants may exist within the same host at any given time, and each variant may have multiple base changes. In vivo analyses of naturally occurring viral variants and in vitro mutagenesis studies have identified some mutations that have a role in viral latency, pathogenesis of liver disease, immune escape, and resistance to antiviral therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       precore/core",
"      </span>",
"      region of the HBV genome encodes the nucleocapsid protein (HBcAg) and HBeAg. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Precore and core promoter variants'",
"      </a>",
"      above.) Initial studies suggested that precore and core promoter variants were associated with more severe liver disease and hepatocellular carcinoma (HCC). However, these variants have also been detected in inactive carriers and patients with minimal liver disease. There are increasing data to support an association between core promoter variants and more severe liver disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical outcomes'",
"      </a>",
"      above.) The pre-S and S regions of the HBV genome contain putative HLA class I-restricted cytotoxic T lymphocyte (CTL) epitope. Several studies reported the detection of S mutants in patients who developed recurrent hepatitis B after liver transplantation despite HBIG prophylaxis, or in children born to HBsAg carrier mothers who developed HBV infection despite receiving HBIG and HBV vaccination. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Immunoprophylaxis failure in orthotopic liver transplant recipients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymerase gene mutations can lead to development of resistance against antiviral agents. They can arise spontaneously but are rarely detected unless they have been selected by exposure to oral nucleos(t)ide analogues. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Polymerase gene mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The X region is crucial for the replication and expression of HBV because the X protein regulates HBV replication through activating and regulating viral and cellular genes. Several studies reported that mutations affecting codons 130 and 131 of the X gene are more common in patients with hepatocellular carcinoma (HCC) than in patients without HCC. These X gene mutations correspond to core promoter mutations that had been reported to be associated with an increased risk of HCC. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'X gene variants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/1\">",
"      Carman W, Thomas H, Domingo E. Viral genetic variation: hepatitis B virus as a clinical example. Lancet 1993; 341:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/2\">",
"      Domingo E, Sabo D, Taniguchi T, Weissmann C. Nucleotide sequence heterogeneity of an RNA phage population. Cell 1978; 13:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/3\">",
"      Summers J, Mason WS. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell 1982; 29:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/4\">",
"      Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/5\">",
"      Oldstone MB. Molecular anatomy of viral persistence. J Virol 1991; 65:6381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/6\">",
"      Blum HE, Liang TJ, Galun E, Wands JR. Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection. Hepatology 1991; 14:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/7\">",
"      Hasegawa K, Huang J, Rogers SA, et al. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/8\">",
"      Uy A, Bruss V, Gerlich WH, et al. Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein. Virology 1986; 155:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/9\">",
"      Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci U S A 1986; 83:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/10\">",
"      Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol 1992; 66:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/11\">",
"      Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70:5845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/12\">",
"      Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/13\">",
"      Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/14\">",
"      Akahane Y, Yamanaka T, Suzuki H, et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/15\">",
"      Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88:4186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/16\">",
"      Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/17\">",
"      Tong SP, Li JS, Vitvitski L, Tr&eacute;po C. Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology 1992; 191:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/18\">",
"      Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87:6599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/19\">",
"      Raimondo G, Tanzi E, Brancatelli S, et al. Is the course of perinatal hepatitis B virus infection influenced by genetic heterogeneity of the virus? J Med Virol 1993; 40:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/20\">",
"      Twu JS, Schloemer RH. Transcription of the human beta interferon gene is inhibited by hepatitis B virus. J Virol 1989; 63:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/21\">",
"      Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/22\">",
"      Jung MC, Diepolder HM, Spengler U, et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995; 69:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/23\">",
"      Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:3442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/24\">",
"      Frelin L, Wahlstr&ouml;m T, Tucker AE, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009; 83:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/25\">",
"      Guidotti LG, Matzke B, Pasquinelli C, et al. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 1996; 70:7056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/26\">",
"      Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997; 71:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/27\">",
"      Hadziyannis S. Hepatitis e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/28\">",
"      Santantonio T, Jung MC, Miska S, et al. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology 1991; 183:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/29\">",
"      Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/30\">",
"      Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/31\">",
"      Ogata N, Miller RH, Ishak KG, Purcell RH. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993; 194:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/32\">",
"      Laskus T, Rakela J, Tong MJ, et al. Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J Hepatol 1994; 20:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/33\">",
"      Fukuda R, Nguyen XT, Ishimura N, et al. X gene and precore region mutations in the hepatitis B virus genome in persons positive for antibody to hepatitis B e antigen: comparison between asymptomatic \"healthy\" carriers and patients with severe chronic active hepatitis. J Infect Dis 1995; 172:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/34\">",
"      Uchida T, Shimojima M, Gotoh K, et al. \"Silent\" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol Immunol 1994; 38:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/35\">",
"      Lindh M, Furuta Y, Ljunggren KK, et al. Detection of hepatitis B virus precore TAG mutant by an amplification-created restriction site method. J Infect Dis 1995; 171:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/36\">",
"      Takahashi K, Ohta Y, Kanai K, et al. Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Arch Virol 1999; 144:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/37\">",
"      Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/38\">",
"      Hussain M, Chu CJ, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003; 41:3699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/39\">",
"      Minamitani S, Nishiguchi S, Kuroki T, et al. Detection by ligase chain reaction of precore mutant of hepatitis B virus. Hepatology 1997; 25:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/40\">",
"      Ballard AL, Boxall EH. Colourimetric point mutation assay: for detection of precore mutants of hepatitis B. J Virol Methods 1997; 67:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/41\">",
"      Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:8102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/42\">",
"      Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995; 21:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/43\">",
"      Chu CM, Yeh CT, Lee CS, et al. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg to anti-Hbe seroconversion. J Clin Microbiol 2002; 31:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/44\">",
"      Kidd-Ljunggren K, Oberg M, Kidd AH. Hepatitis B virus X gene 1751 to 1764 mutations: implications for HBeAg status and disease. J Gen Virol 1997; 78 ( Pt 6):1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/45\">",
"      Chan HL, Leung NW, Hussain M, et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/46\">",
"      Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/47\">",
"      Takahashi K, Aoyama K, Ohno N, et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995; 76 ( Pt 12):3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/48\">",
"      Kurosaki M, Enomoto N, Asahina Y, et al. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996; 49:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/49\">",
"      Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/50\">",
"      Zarski JP, Marcellin P, Cohard M, et al. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. J Hepatol 1994; 20:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/51\">",
"      Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/52\">",
"      Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/53\">",
"      Naoumov NV, Schneider R, Gr&ouml;tzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/54\">",
"      Shindo M, Hamada K, Koya S, et al. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/55\">",
"      Schalm SW, Thomas HC, Hadziyannis SJ. Chronic hepatitis B. Prog Liver Dis 1990; 9:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/56\">",
"      Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method. J Infect Dis 1997; 175:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/57\">",
"      Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/58\">",
"      Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/59\">",
"      Lindh M, Hannoun C, Dhillon AP, et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/60\">",
"      Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/61\">",
"      Fang ZL, Ling R, Wang SS, et al. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J Med Virol 1998; 56:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/62\">",
"      Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999; 29:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/63\">",
"      Gaglio P, Singh S, Degertekin B, et al. Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl 2008; 14:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/64\">",
"      Bonino F, Brunetto MR. Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. J Hepatol 1993; 18:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/65\">",
"      Yuen MF, Tanaka Y, Ng IO, et al. Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. J Viral Hepat 2005; 12:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/66\">",
"      Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002; 186:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/67\">",
"      Yuen MF, Tanaka Y, Mizokami M, et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/68\">",
"      Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/69\">",
"      Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008; 57:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/70\">",
"      Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/71\">",
"      Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/72\">",
"      Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/73\">",
"      Kosaka Y, Takase K, Kojima M, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/74\">",
"      Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/75\">",
"      Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/76\">",
"      Karayiannis P, Alexopoulou A, Hadziyannis S, et al. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. Hepatology 1995; 22:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/77\">",
"      Jardi R, Rodriguez F, Buti M, et al. Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol 2004; 40:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/78\">",
"      Peng XM, Huang GM, Li JG, et al. High level of hepatitis B virus DNA after HBeAg-to-anti-HBe seroconversion is related to coexistence of mutations in its precore and basal core promoter. World J Gastroenterol 2005; 11:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/79\">",
"      Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/80\">",
"      Oliveri F, Santantonio T, Bellati G, et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/81\">",
"      Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/82\">",
"      Fattovich G, McIntyre G, Thursz M, et al. Hepatitis B virus precore/core variation and interferon therapy. Hepatology 1995; 22:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/83\">",
"      Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/84\">",
"      Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/85\">",
"      Marrone A, Zampino R, Luongo G, et al. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology 2003; 46:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/86\">",
"      Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. Antivir Ther 2012; 17:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/87\">",
"      Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/88\">",
"      Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/89\">",
"      Tacke F, Gehrke C, Luedde T, et al. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004; 78:8524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/90\">",
"      Bhatnagar PK, Papas E, Blum HE, et al. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc Natl Acad Sci U S A 1982; 79:4400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/91\">",
"      Brown SE, Stanley C, Howard CR, et al. Antibody responses to recombinant and plasma derived hepatitis B vaccines. Br Med J (Clin Res Ed) 1986; 292:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/92\">",
"      Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/93\">",
"      Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/94\">",
"      Pircher H, Moskophidis D, Rohrer U, et al. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990; 346:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/95\">",
"      Waters JA, Kennedy M, Voet P, et al. Loss of the common \"A\" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/96\">",
"      Oon CJ, Chen WN, Goo KS, Goh KT. Intra-familial evidence of horizontal transmission of hepatitis B virus surface antigen mutant G145R. J Infect 2000; 41:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/97\">",
"      Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/98\">",
"      Br&eacute;chot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely \"occult\"? Hepatology 2001; 34:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/99\">",
"      Carman WF, Van Deursen FJ, Mimms LT, et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology 1997; 26:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/100\">",
"      Grethe S, Monazahian M, B&ouml;hme I, Thomssen R. Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 1998; 72:7692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/101\">",
"      Hou J, Karayiannis P, Waters J, et al. A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology 1995; 21:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/102\">",
"      Kato J, Hasegawa K, Torii N, et al. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996; 23:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/103\">",
"      Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001; 34:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/104\">",
"      Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8:3867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/105\">",
"      Johnson MS, McClure MA, Feng DF, et al. Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci U S A 1986; 83:7648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/106\">",
"      Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/107\">",
"      Rossner MT. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992; 36:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/108\">",
"      Yoo YD, Ueda H, Park K, et al. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest 1996; 97:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/6/6250/abstract/109\">",
"      Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996; 348:625.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3639 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D4E9CFABE8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6250=[""].join("\n");
var outline_f6_6_6250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H97394206\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRECORE AND CORE PROMOTER VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Precore variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Core promoter variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relationship to HBeAg status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Relationship to HBeAg negative chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fulminant hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serum quantitative HBV DNA levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interferon (IFN) therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nucleoside analogue therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRE-S/S VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vaccine-escape mutants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immunoprophylaxis failure in orthotopic liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Viral persistence in HBsAg-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POLYMERASE GENE MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      X GENE VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97394206\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_6_6251="Ovarian cancer symptoms";
var content_f6_6_6251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of symptom categories in women with ovarian cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Goff BA, Mandel L, Muntz HG. Melancon CH. Cancer 2000; 89:2068.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6251=[""].join("\n");
var outline_f6_6_6251=null;
var title_f6_6_6252="Treatment chronic refractory ITP";
var content_f6_6_6252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management options in chronic refractory immune thrombocytopenia (ITP) unresponsive to initial glucocorticoid therapy, splenectomy, and rituximab",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Management",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Observation",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         No bleeding symptoms; platelet count &ge;30,000/microL",
"        </p>",
"       </td>",
"       <td>",
"        The platelet count may remain stable; most patients will be asymptomatic; patients with bleeding symptoms or who are at high risk of bleeding may require treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Thrombopoiesis-stimulating agents",
"        </strong>",
"       </td>",
"       <td>",
"        Persistent, symptomatic thrombocytopenia; platelet count &lt;20,000 to 30,000/microL; or&nbsp;potential risk for clinically important bleeding",
"       </td>",
"       <td>",
"        The most important indication for these agents is in patients who have failed to achieve a durable response with a safe platelet count&nbsp;after initial and second line treatments. In most patients, administration of these agents will result in a safe platelet count for as long as the agent is&nbsp;continued.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Observation with supportive care",
"        </strong>",
"        (eg, short courses of steroids or IVIG as needed for bleeding symptoms or preparation for procedures; platelet and/or red cell transfusions)",
"       </td>",
"       <td>",
"        Lack of response&nbsp;to treatment with thrombopoiesis-stimulating agents",
"       </td>",
"       <td>",
"        This may be the option preferred by many patients. Some patients may have minimal or no bleeding in spite of persistent severe thrombocytopenia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Immunosuppressive agents",
"        </strong>",
"        (eg, cyclophosphamide vincristine, vinblastine, azathioprine, danazol, mycophenolate mofetil, cyclosporine, etc.)",
"       </td>",
"       <td>",
"        Persistent thrombocytopenia with bleeding symptoms, platelet count &lt;20,000/microL",
"       </td>",
"       <td>",
"        Goal is only a safe platelet count with control of bleeding.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6252=[""].join("\n");
var outline_f6_6_6252=null;
var title_f6_6_6253="Normal growth rate in children";
var content_f6_6_6253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    \"Rule of fives\" for estimating normal growth rates in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 152px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal length or height at various ages during childhood, and the growth rate between those timepoints, are approximated by multiples of five, as shown above. Actual height and growth rate in a healthy child can vary substantially around these approximations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6253=[""].join("\n");
var outline_f6_6_6253=null;
var title_f6_6_6254="Zoonoses from dogs A";
var content_f6_6_6254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80280%7EID%2F54607%7EID%2F67427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80280%7EID%2F54607%7EID%2F67427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses dogs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Canine symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Infectious saliva",
"       </td>",
"       <td>",
"        Rabies",
"       </td>",
"       <td>",
"        Acute progressive encephalitis",
"       </td>",
"       <td>",
"        Stages: prodromal, furious, and paralytic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasteurella",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, septic arthritis, osteomyelitis",
"       </td>",
"       <td>",
"        Normal flora of oral cavity",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capnocytophaga",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, sepsis, meningitis",
"       </td>",
"       <td>",
"        Normal flora of oral cavity",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucella",
"       </td>",
"       <td colspan=\"1\">",
"        Fever of unknown origin; varied and nonspecific symptoms",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Fecal",
"       </td>",
"       <td>",
"        Salmonella Cryptosporidium Giardia",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter",
"       </td>",
"       <td>",
"        Abdominal pain and diarrhea",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxocara canis",
"       </td>",
"       <td>",
"        Visceral larva migrans and ocular larva migrans",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ancylostoma caninum",
"       </td>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus granulosus",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Most common in ranching areas of the Mediterranean, South America, and Australia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipylidium caninum",
"       </td>",
"       <td>",
"        Asymptomatic to abdominal pain, diarrhea, pruritus ani, and urticaria",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses dogs, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Canine symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Insect bites",
"       </td>",
"       <td>",
"        B. burgdorferi",
"       </td>",
"       <td>",
"        Erythema migrans, Lyme disease (multisystem inflammatory disease)",
"       </td>",
"       <td>",
"        Sudden onset lameness, swollen joints",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsia rickettsii",
"       </td>",
"       <td>",
"        Rocky Mountain spotted fever, Fever, headache, followed by rash",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        North America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichia chaffeensis and Anaplasma phagocytophilum",
"       </td>",
"       <td>",
"        Ehrlichiosis, Fever with variable symptoms (malaise, myalgias, headache)",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Focal areas of United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesia microti or B. divergens",
"       </td>",
"       <td>",
"        Babesiosis, Asymptomatic to severe hemolytic anemia",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Babesia microti (United States, primarily Northeast); Babesia divergens (Europe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Francisella tularensis",
"       </td>",
"       <td>",
"        Tularemia, Abrupt onset fever, chills, HA, single erythematous papuloulcerative lesion with eschar",
"       </td>",
"       <td>",
"        Fever, loss of appetite",
"       </td>",
"       <td>",
"        Majority in south central United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis",
"       </td>",
"       <td>",
"        Plague, Abrupt onset fever, chills, HA Acute bubo",
"       </td>",
"       <td>",
"        Self-limited illness",
"       </td>",
"       <td>",
"        Worldwide except Australia; in United States, mostly Southwestern states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dirofilaria immitis",
"       </td>",
"       <td>",
"        Urticarial skin eruption; \"coin lesion\" in lung",
"       </td>",
"       <td>",
"        Heartworm Most asymptomatic Exercise intolerance Hemoptysis",
"       </td>",
"       <td>",
"        Worldwide; particularly common in the Mediterranean",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leishmania",
"       </td>",
"       <td>",
"        Asymptomatic to cutaneous, mucocutaneous, or visceral disease",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Focal areas of world",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses dogs, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Canine symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Aerosol",
"       </td>",
"       <td>",
"        Bordetella bronchiseptica",
"       </td>",
"       <td>",
"        Asymptomatic to upper respiratory tract infections to pneumonia",
"       </td>",
"       <td>",
"        Kennel cough",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii",
"       </td>",
"       <td>",
"        Q fever, including A self-limited flu-like illness, +/- pneumonia, +/- hepatitis, +/- endocarditis",
"       </td>",
"       <td>",
"        Asymptomatic; infection may cause abortion or rapid death of newborn pups",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine",
"       </td>",
"       <td>",
"        Leptospira interrogans",
"       </td>",
"       <td>",
"        Leptosiprosis, subclinical to severe, potentially fatal illness",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6254=[""].join("\n");
var outline_f6_6_6254=null;
var title_f6_6_6255="Pregnancy rates with ART at maternal age 40 and older";
var content_f6_6_6255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in pregnancies, live births, and singleton live births among women aged 40 or older,* 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Success rates decline with each year of age and are particularly low for women 40 or older. The above figure shows the percentages of pregnancies, live births, and singleton live births in 2006 for women 40 or older who used fresh nondonor eggs or embryos. The average chance for pregnancy was 23 percent for women age 40; the percentage of ART cycles resulting in live births for this age was about 15 percent, and the percentage of ART cycles resulting in singleton live births was about 12 percent. All percentages dropped steadily with each 1-year increase in age. For women older than 44, the percentages of live births and singleton live births were both a little more than 1 percent. Women 40 or older generally have much higher success rates using donor eggs.",
"    <div class=\"footnotes\">",
"     * For consistency, all percentages are based on cycles started.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_6_6255=[""].join("\n");
var outline_f6_6_6255=null;
